Identification of genes with specific expression in pancreatic cancer by cDNA representational difference analysis

Department of Internal Medicine I, University of Ulm, Germany.
Genes Chromosomes and Cancer (Impact Factor: 4.04). 07/1997; 19(2):97-103. DOI: 10.1002/(SICI)1098-2264(199706)19:23.0.CO;2-V
Source: PubMed


cDNA representational difference analysis (cDNA-RDA) is a polymerase-chain-reaction-coupled subtractive and kinetic enrichment procedure for the isolation of differentially expressed genes. In this study, the technique was used to isolate novel genes specifically expressed in pancreatic cancer. cDNA-RDA was done on cDNA reverse transcribed from a poly(A)+ mRNA pool made from 10 cancer tissues (tester) by using as a driver a cDNA from a poly(A)+ mRNA pool made from a combination of 10 tissues of chronic pancreatitis and 10 healthy pancreatic tissues. The use of chronic pancreatitis in addition to healthy pancreas mRNA in the driver preparation eliminated the influence of stromal tissue components present as contamination in the cancer-specific preparations. Such cDNA-RDA led to the isolation of 16 distinct, cancer-specific gene fragments. These were confirmed to be overexpressed in pancreatic cancer tissues by Northern blot analysis. Sequence analysis revealed homologies to five genes previously implicated in the carcinogenesis of the pancreas or other tissues. Eleven fragments had no significant homology to any known gene and thus represent novel candidate disease genes. The experiments demonstrate that cDNA-RDA is a reproducible and highly efficient method for the identification of novel genes with cancer-specific expression.

Full-text preview

Available from:
  • Source
    • "TM4SF5 (20,823 Da) is a transmembrane glycoprotein; as a family group, it is related to the tetraspanin family (transmembrane 4 L six family), including TM4SF1 (L6, L6-Ag), TM4SF4 (IL-TIMP), TM4SF518 (L6D), and TM4SF20 [61, 62]. TM4SF5 is highly expressed in diverse types of cancers, including liver, pancreatic, gastric, colon, adrenocorticotropic hormone (corticotropin)-negative bronchial carcinoid tumors, soft-tissue sarcoma, nonendocrine lung, and papilla vateri carcinoma [63, 64, 65, 66]. Similar to tetraspanins (i.e., transmembrane 4 superfamily, TM4SFs), TM4SF5 has four transmembrane domains (TM1-TM4), short cytoplasmic domains at their N- and C-termini, an ICL between TM2 and TM4, two extracellular loops, a smaller extracellular loop between TM1 and TM2, and a larger extracellular loop between TM3 and TM4 [61, 62]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The epithelial-mesenchymal transition (EMT) is one mechanism by which cells with mesenchymal features can be generated and is a fundamental event in morphogenesis. Recently, invasion and metastasis of cancer cells from the primary tumor are now thought to be initiated by the developmental process termed the EMT, whereby epithelial cells lose cell polarity and cell-cell interactions, and gain mesenchymal phenotypes with increased migratory and invasive properties. The EMT is believed to be an important step in metastasis and is implicated in cancer progression, although the influence of the EMT in clinical specimens has been debated. This review presents the recent results of two cell surface proteins, the functions and underlying mechanisms of which have recently begun to be demonstrated, as novel regulators of the molecular networks that induce the EMT and cancer progression.
    Full-text · Article · Mar 2014
  • Source
    • "Comparing expression profiles from primary tumors with samples from histologically non-malignant pancreatic tissue and chronic pancreatitis (CP) we identified a 147-gene signature correlated with primary pancreatic tumor. This strategy was devised to favor the identification of tumor specific markers rather than transcripts associated with the stromal cell component, which is augmented in both tumor and CP samples [36,37]. We sought to validate the pancreatic cancer expression signature by performing a meta-analysis with published gene expression studies of pancreatic cancer. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is known by its aggressiveness and lack of effective therapeutic options. Thus, improvement in current knowledge of molecular changes associated with pancreatic cancer is urgently needed to explore novel venues of diagnostics and treatment of this dismal disease. While there is mounting evidence that long noncoding RNAs (lncRNAs) transcribed from intronic and intergenic regions of the human genome may play different roles in the regulation of gene expression in normal and cancer cells, their expression pattern and biological relevance in pancreatic cancer is currently unknown. In the present work we investigated the relative abundance of a collection of lncRNAs in patients' pancreatic tissue samples aiming at identifying gene expression profiles correlated to pancreatic cancer and metastasis. Custom 3,355-element spotted cDNA microarray interrogating protein-coding genes and putative lncRNA were used to obtain expression profiles from 38 clinical samples of tumor and non-tumor pancreatic tissues. Bioinformatics analyses were performed to characterize structure and conservation of lncRNAs expressed in pancreatic tissues, as well as to identify expression signatures correlated to tissue histology. Strand-specific reverse transcription followed by PCR and qRT-PCR were employed to determine strandedness of lncRNAs and to validate microarray results, respectively. We show that subsets of intronic/intergenic lncRNAs are expressed across tumor and non-tumor pancreatic tissue samples. Enrichment of promoter-associated chromatin marks and over-representation of conserved DNA elements and stable secondary structure predictions suggest that these transcripts are generated from independent transcriptional units and that at least a fraction is under evolutionary selection, and thus potentially functional.Statistically significant expression signatures comprising protein-coding mRNAs and lncRNAs that correlate to PDAC or to pancreatic cancer metastasis were identified. Interestingly, loci harboring intronic lncRNAs differentially expressed in PDAC metastases were enriched in genes associated to the MAPK pathway. Orientation-specific RT-PCR documented that intronic transcripts are expressed in sense, antisense or both orientations relative to protein-coding mRNAs. Differential expression of a subset of intronic lncRNAs (PPP3CB, MAP3K14 and DAPK1 loci) in metastatic samples was confirmed by Real-Time PCR. Our findings reveal sets of intronic lncRNAs expressed in pancreatic tissues whose abundance is correlated to PDAC or metastasis, thus pointing to the potential relevance of this class of transcripts in biological processes related to malignant transformation and metastasis in pancreatic cancer.
    Full-text · Article · Nov 2011 · Molecular Cancer
  • Source
    • "Microarray analyses have consistently found it to be one of the most upregulated genes in advanced prostate cancer (Dhanasekaran et al., 2001; Magee et al., 2001). Other transmembrane serine proteases implicated in cancer progression are membrane-type serine protease-1/matriptase in breast cancer (Shi et al., 1993), TMPRSS2 in prostate cancer (Afar et al., 2001) and TMPRSS4 in pancreatic cancer (Gress et al., 1997). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The matrix metalloproteinases(MMP)-2 and -9, also known as the gelatinases have been long recognized as major contributors to the proteolytic degradation of extracellular matrix during tumor invasion. In the recent years, a plethora of non-matrix proteins have also been identified as gelatinase substrates thus significantly broadening our understanding of these enzymes as proteolytic executors and regulators in various physiological and pathological states including embryonic growth and development, angiogenesis and tumor progression, inflammation, infective diseases, degenerative diseases of the brain and vascular diseases. Although the effect of broad-spectrum inhibitors of MMPs in the treatment of cancer has been disappointing in clinical trials, novel mechanisms of gelatinase inhibition have been now identified. Inhibition of the association of the gelatinases with cell-surface integrins appears to offer highly specific means to target these enzymes without inhibiting their catalytic activity in multiple cell types including endothelial cells, tumor cells and leukocytes. Here, we review the multiple functions of the gelatinases in cancer, and especially their role in the tumor cell migration and invasion.
    Preview · Article · Jun 2005 · Biochimica et Biophysica Acta
Show more